This trial is no longer recruiting

Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.

Not recruiting
Phase 3

Xeomin

Sponsor:

Merz Therapeutics GmbH

Code:

NCT07018713

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Xeomin

Placebo

Study Details

Brief summary:

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.

Trial details include:

  • Trial duration: 52 to 55 weeks;

  • Screening period: 4 to 5 weeks;
  • Treatment duration: 4 treatments, each about 12 weeks apart; and
  • Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.

Conditions

Chronic Migraine

Study ID

NCT07018713

Start date

Aug 21, 2025

Status verified date

Oct, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participant has a diagnosis of CM with or without aura according to the International Classification of Headache Disorders Edition 3 criteria for ≥ 12 months and is able to distinguish migraine headaches from all other types of headaches;
  • Participant age < 50 years at the time of migraine onset;
  • Participant meeting the following headache and migraine day criteria in each of the 3 months prior to screening: history of ≥ 15 headache days per month and history of ≥ 8 migraine days per month; and
  • During the last 28 days of the screening period, participant experiencing: ≥ 15 headache days and ≥ 8 migraine days that qualify as such per the headache diary.

Exclusion Criteria:

  • Diagnosis of other primary headache types, except tension-type headache, which is permitted;
  • Diagnosis of aura without headache, migraine with brainstem aura, hemicrania continua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aura without infarction, migraine aura-triggered seizure, or previous migrainous infarction;
  • Diagnosis of secondary headache types, except medication overuse headache, which is permitted;
  • Currently taking > 1 prescribed drug for the preventive treatment of migraine;
  • Discontinuation of anti-calcitonin gene-related peptide (CGRP) / anti-CGRP receptor monoclonal antibody treatment less than 5 months prior to screening.

Study Design

Enrollment

808 participants

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Xeomin Dose A

Placebo-controlled period + extension period: Xeomin injections at pericranial and cervical points (dose A)

experimental: Xeomin Dose B

Placebo-controlled period + extension period: Xeomin injections at pericranial and cervical point (dose B)

placebo comparator: Placebo

Placebo-controlled period: Placebo injections at pericranial and cervical points.

Extension period: Xeomin injections at pericranial and cervical points (dose A)

Interventions

Xeomin

Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)

Placebo

Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)

Primary outcome measure

  • Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A [ Time Frame: Baseline to month 6 ]

Central Contacts and Locations

More Information

Sponsor

Merz Therapeutics GmbH

Last update posted

Oct 14, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Merz Therapeutics GmbH on 2026-10-14. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.